Contributions
Abstract: P684
Type: Poster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Objective: To determine if natalizumab can impact the Multiple Sclerosis Disease Severity score over a period of nine years.
Background: The Multiple Sclerosis severity score (MSSS) combines via an algorithm, disease duration with the expanded disease status score (EDSS). It is a measure of the rate of disability accumulation in multiple sclerosis (MS) patients i.e. disease severity. Studies have shown that several accepted MS therapies including interferon beta, glatiramer acetate and azathioprine do not impact the MSSS.
Methods: This a single center, retrospective, chart review. Only patients with well documented, uninterrupted natalizumab therapy were considered. The MSSS was determined by using the table in the manuscript by Roxburgh et al.
Results: We recorded data on 143 patients (111 female, 32 males) with mean age of 42 years, mean disease duration of 10.5 years (0-40 years). The mean EDSS was 3.1 and mean MSSS was 4.52. The follow-up ranged from 1-9 years with a mean of 4 years and a total of 586 patient-years.
The overall, annual, mean MSSS decreased significantly (P=0.004) from baseline beginning in year 2 and was sustained for the rest of the 9 years period. Baseline EDSS appeared to influence the subsequent change in MSSS with patients starting with a moderate level of disability (EDSS 3.0-5.5) showing the greatest decrease in MSSS (5.5 to 2.0, p=0.01). Baseline MSSS showed a different pattern with patients with the greatest level of disease severity (MSS≥7.0) achieving the greatest decrease (8.0 to 3.2 P=0.0005). Baseline disease duration showed an inverse relationship with the patients in the >10 years group showing no change in MSSS and those in the < 5 years group showed the greatest change in MSSS (p< 0.001).
Conclusions: Our study corroborates with the Swedish Registry and demonstrates that natalizumab impacts significantly on MS disease severity. The benefit in our patient population became apparent in the second year of therapy and was sustained through years 3 to 9. The response was the greatest in patients with either a moderate baseline EDSS (3.0-5.5), a high MSSS (≥ 7.0) or a short disease duration (< 5 years).
Disclosure:
F. Jacques has received honorariums from several companies. Clinique Neuro-Outaouais operates an infusion clinic where Natalizumab (Tysabri) is administered.
J. Fortin is an employee of Clinique Neuro-Outaouais.
V. Sikati Foko is an employee of Clinique Neuro-Outaouais.
Abstract: P684
Type: Poster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Objective: To determine if natalizumab can impact the Multiple Sclerosis Disease Severity score over a period of nine years.
Background: The Multiple Sclerosis severity score (MSSS) combines via an algorithm, disease duration with the expanded disease status score (EDSS). It is a measure of the rate of disability accumulation in multiple sclerosis (MS) patients i.e. disease severity. Studies have shown that several accepted MS therapies including interferon beta, glatiramer acetate and azathioprine do not impact the MSSS.
Methods: This a single center, retrospective, chart review. Only patients with well documented, uninterrupted natalizumab therapy were considered. The MSSS was determined by using the table in the manuscript by Roxburgh et al.
Results: We recorded data on 143 patients (111 female, 32 males) with mean age of 42 years, mean disease duration of 10.5 years (0-40 years). The mean EDSS was 3.1 and mean MSSS was 4.52. The follow-up ranged from 1-9 years with a mean of 4 years and a total of 586 patient-years.
The overall, annual, mean MSSS decreased significantly (P=0.004) from baseline beginning in year 2 and was sustained for the rest of the 9 years period. Baseline EDSS appeared to influence the subsequent change in MSSS with patients starting with a moderate level of disability (EDSS 3.0-5.5) showing the greatest decrease in MSSS (5.5 to 2.0, p=0.01). Baseline MSSS showed a different pattern with patients with the greatest level of disease severity (MSS≥7.0) achieving the greatest decrease (8.0 to 3.2 P=0.0005). Baseline disease duration showed an inverse relationship with the patients in the >10 years group showing no change in MSSS and those in the < 5 years group showed the greatest change in MSSS (p< 0.001).
Conclusions: Our study corroborates with the Swedish Registry and demonstrates that natalizumab impacts significantly on MS disease severity. The benefit in our patient population became apparent in the second year of therapy and was sustained through years 3 to 9. The response was the greatest in patients with either a moderate baseline EDSS (3.0-5.5), a high MSSS (≥ 7.0) or a short disease duration (< 5 years).
Disclosure:
F. Jacques has received honorariums from several companies. Clinique Neuro-Outaouais operates an infusion clinic where Natalizumab (Tysabri) is administered.
J. Fortin is an employee of Clinique Neuro-Outaouais.
V. Sikati Foko is an employee of Clinique Neuro-Outaouais.